Genprex (GNPX) said Tuesday a safety review committee approved the increase in dosage to the maximum level of 0.12 mg/kg in the phase 1 trial of its drug candidate, Reqorsa, to treat small-cell lung cancer.
The "escalation to the highest dose group" comes after the company completed giving the 0.09 mg/kg dose to participants in the Acclaim-3 clinical trial of Reqorsa in combination with atezolizumab, which is sold under the Tecentriq brand name of Genentech.
The trial has not resulted in "dose limiting toxicities" in the 0.09 mg/kg dose group, demonstrating the drug's safety profile, the company said.
The phase 1 trial's primary endpoint is determining the maximum tolerated or recommended phase 2 dose. The phase 2 portion's primary endpoint is to establish the 18-week progression-free survival rate from the time the maintenance therapy begins, Genprex said.
Shares of the Genprex were up nearly 5% in recent trading.
Price: 0.37, Change: +0.02, Percent Change: +4.79
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。